ALXO
ALX Oncology Holdings Inc.
$1.27
+$0.06(+4.96%)
33
Overall
--
Value
33
Tech
--
Quality
Market Cap
$57.84M
Volume
738.99K
52W Range
$0.40 - $2.08
Target Price
$2.25
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $1.2M | -- | -- | -- | -- | ||
| Total Revenue | $1.2M | -- | -- | -- | -- | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | $1.1M | -- | -- | -- | -- | ||
| GROSS PROFIT | |||||||
| Gross Profit | $107.0K | -- | -- | -- | -- | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $44.8M | $83.6M | $127.4M | $170.3M | $142.5M | ||
| Research & Development | $29.0M | $60.2M | $98.4M | $141.8M | $116.4M | ||
| Research Expense | $29.0M | $60.2M | $98.4M | $141.8M | $116.4M | ||
| Selling, General & Administrative | $14.8M | $23.4M | $29.0M | $28.5M | $26.1M | ||
| General & Administrative Expenses | $14.8M | $23.4M | $29.0M | $28.5M | $26.1M | ||
| Salaries & Wages | -- | -- | $23.8M | $26.3M | $27.1M | ||
| Depreciation & Amortization | $200.0K | -- | $300.0K | $800.0K | $900.0K | ||
| Depreciation & Amortization | $200.0K | -- | $300.0K | $800.0K | $900.0K | ||
| Amortization | -- | $369.0K | $447.0K | $493.0K | $962.0K | ||
| Other Operating Expenses | $-240.0K | $-494.0K | $-443.0K | $-1.4M | $-1.1M | ||
| OPERATING INCOME | |||||||
| Operating income | $-43.7M | $-83.6M | $-127.4M | $-170.3M | $-142.5M | ||
| EBITDA | $-43.5M | $-82.7M | $-121.7M | $-158.4M | $-131.7M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $811.0K | $13.0K | $238.0K | $1.6M | $1.7M | ||
| Intinc | $-811.0K | $91.0K | $4.3M | $10.6M | $9.4M | ||
| Net Non-Operating Interest Income/Expense | $-811.0K | $91.0K | $-4.0M | $9.1M | $7.6M | ||
| Other Income/Expense | $1.0M | $20.0K | $-22.0K | $-389.0K | $20.0K | ||
| Other Special Charges | $-1.0M | $-20.0K | $-22.0K | $389.0K | $-20.0K | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-43.7M | $-83.5M | $-123.2M | $-160.7M | $-134.7M | ||
| Pre-Tax Income | $-45.5M | $-83.5M | $-123.4M | $-160.8M | $-134.8M | ||
| INCOME TAX | |||||||
| Tax Provision | $241.0K | $-21.0K | $64.0K | $-1.5M | $-1.6M | ||
| NET INCOME | |||||||
| Net Income | $-45.7M | $-83.5M | $-123.5M | $-160.8M | $-134.8M | ||
| Net Income (Continuing Operations) | $-45.7M | $-83.5M | $-123.5M | $-160.8M | $-134.8M | ||
| Net Income (Discontinued Operations) | $-45.7M | $-83.5M | $-123.5M | $-160.8M | $-134.8M | ||
| Net Income (Common Stockholders) | $-50.9M | $-83.5M | $-123.5M | $-160.8M | $-134.8M | ||
| Normalized Income | -- | -- | -- | -- | $-136.4M | ||
| TOTALS | |||||||
| Total Expenses | $45.9M | $83.6M | $127.4M | $170.3M | $142.5M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $18.5M | $40.3M | $40.7M | $43.0M | $52.2M | ||
| Average Shares Outstanding (Diluted) | $18.5M | -- | $40.7M | $43.0M | $52.2M | ||
| Shares Outstanding | $40.1M | $40.6M | $40.9M | $50.2M | $53.4M | ||
| Basic EPS | $-2.76 | $-2.07 | $-3.03 | $-3.74 | $-2.58 | ||
| Basic EPS (Continuing Operations) | $-2.76 | $-2.07 | $-3.03 | $-3.74 | $-2.58 | ||
| Diluted EPS | $-2.76 | $-2.07 | $-3.03 | $-3.74 | $-2.58 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.03 | $-3.74 | $-2.58 | ||
| OTHER METRICS | |||||||
| Accrued Preferred Stock Dividends | $5.2M | -- | -- | -- | -- | ||
| Other Gand A | $14.8M | $23.4M | $29.0M | $28.5M | $26.1M | ||
| Otherunder Preferred Stock Dividend | $5.2M | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $5.2M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALXO | $1.27 | +5.0% | 738.99K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ALX Oncology Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW